GENETIC TECHNOLOGIES LIMITED — Director's Dealing 2019

Oct 31, 2019

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	5 February 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	RIP Opportunities Pty Ltd A/C> Irwin Biotech Nominees Pty Ltd A/C>
Date of change	28 October 2019

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

No. of securities held prior to change	Irwin Biotech Nominees P/L **A/C> 6,200,000 ordinary shares Irwin Biotech Nominees Pty Ltd **A/C> 5,000,000 ordinary shares 5,000,000 Performance Rights Irwin Biotech Nominees Pty Ltd 2,000,000 ordinary shares Irwin Biotech Nominees Pty Ltd 26,582,700 ordinary shares (represented by 44,305 American Depositary Receipts) RIP Opportunities Pty Ltd 7,500,000 ordinary shares (represented by 12,500 American Depositary Receipts)
Class	Ordinary Fully Paid Shares
Number acquired	200,849,309 Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.004 per Share

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change

Irwin Biotech Nominees P/L **A/C> 6,200,000 ordinary shares Irwin Biotech Nominees Pty Ltd **A/C> 80,849,310 ordinary shares 5,000,000 Performance Rights Irwin Biotech Nominees Pty Ltd 2,000,000 ordinary shares Irwin Biotech Nominees Pty Ltd 26,582,700 ordinary shares (represented by 44,305 American Depositary Receipts) RIP Opportunities Pty Ltd 7,500,000 ordinary shares (represented by 12,500 American Depositary Receipts) RIP Opportunities Pty Ltd **Fund A/C> 124,999,999 ordinary shares

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Shares issued pursuant to the sub- underwriting of non-renounceable rights issue.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Sub-underwriting Agreement
Nature of interest	Indirect
Name of registered holder (if issued securities)	RIP Opportunities Pty Ltd Irwin Biotech Nominees Pty Ltd
Date of change	29 October 2019
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Interest acquired	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of $0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Issued in part consideration for sub-underwriting of the Company’s Non-Renounceable Rights.
Interest after change	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of $0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Genetic Technologies Limited

ABN: 17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jerzy Muchnicki
Date of last notice	5 February 2018

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	MJGD Nominees Pty Ltd
Date of change	28 October 2019
No. of securities held prior to change	MJGD Nominees Pty Ltd 6,254,115 ordinary shares JGM Investment Group (The Muchnicki Family A/C) 9,400,000 ordinary shares MJGD Nominees Pty Ltd (BSMI A/C) 4,849,129 ordinary shares 6,250,000 Performance Rights
Class	Ordinary Fully Paid Shares
Number acquired	200,849,309 Shares
Number disposed	Nil

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$0.004 per Share
No. of securities held after change	MJGD Nominees Pty Ltd 207,103,424 ordinary shares JGM Investment Group (The Muchnicki Family A/C) 9,400,000 ordinary shares MJGD Nominees Pty Ltd (BSMI A/C) 4,849,129 ordinary shares 6,250,000 Performance Rights
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Shares issued pursuant to the sub- underwriting of non-renounceable rights issue.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	Sub-underwriting Agreement
Nature of interest	Indirect
Name of registered holder (if issued securities)	MJGD Nominees Pty Ltd
Date of change	29 October 2019
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of $0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.
Interest disposed	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Issued in part consideration for sub-underwriting of the Company’s Non-Renounceable Rights.
Interest after change	Agreement to be issued, subject to shareholder approval, 125,000,000 unlisted options with an exercise price of $0.008 per option, each option exercisable for one fully paid ordinary share in the Company at any time up to and including 5pm on 29 October 2022.

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?
If prior written clearance was provided, on what date was this provided?

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3